Literature DB >> 19820943

Intraarticular adalimumab in a patient with pigmented villonodular synovitis.

Senol Kobak1.   

Abstract

Pigmented villonodular synovitis is a chronic inflammatory disease progressing with histological villonodular hyperplasia in synovium, fibrosis and accumulation of hemosiderin. Knee joint is frequently involved leading to severe joint damage and disability in untreated cases. Treatment options include surgical intervention or radio-synovectomy with intraarticular yttrium-90. The case presented here includes significant clinical and radiological disease regression after intraarticular adalimumab in a patient diagnosed with radiologically and histologically confirmed pigmented villonodular synovitis who did not consent to surgical intervention.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19820943     DOI: 10.1007/s00296-009-1185-z

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  13 in total

Review 1.  Pigmented villonodular synovitis.

Authors:  Onder Ofluoglu
Journal:  Orthop Clin North Am       Date:  2006-01       Impact factor: 2.472

2.  Giant cells in pigmented villo nodular synovitis express an osteoclast phenotype.

Authors:  S D Neale; R Kristelly; R Gundle; J M Quinn; N A Athanasou
Journal:  J Clin Pathol       Date:  1997-07       Impact factor: 3.411

3.  Different mechanisms of synovial hyperplasia in rheumatoid arthritis and pigmented villonodular synovitis: the role of telomerase activity in synovial proliferation.

Authors:  K Yudoh; H Matsuno; T Nezuka; T Kimura
Journal:  Arthritis Rheum       Date:  1999-04

4.  [Iron deposits, cell populations and proliferative activity in pigmented villonodular synovitis of the knee joint].

Authors:  T Aigner; S Oehler; H G Niedobitek; G Fassbender; T Kirchner
Journal:  Verh Dtsch Ges Pathol       Date:  1998

5.  Rheumatoid arthritis and pigmented villonodular synovitis: comparative analysis of cell polyploidy, cell cycle phases and expression of macrophage and fibroblast markers in proliferating synovial cells.

Authors:  I Berger; H Weckauf; B Helmchen; V Ehemann; R Penzel; B Fink; L Bernd; F Autschbach
Journal:  Histopathology       Date:  2005-05       Impact factor: 5.087

6.  Cell characterization of mononuclear and giant cells constituting pigmented villonodular synovitis.

Authors:  Wataru Yoshida; Miwa Uzuki; Akira Kurose; Masaaki Yoshida; Jun Nishida; Tadashi Shimamura; Takashi Sawai
Journal:  Hum Pathol       Date:  2003-01       Impact factor: 3.466

7.  Cytokine and matrix metalloproteinase expression in pigmented villonodular synovitis may mediate bone and cartilage destruction.

Authors:  R J O'Keefe; R N Rosier; L A Teot; J M Stewart; D G Hicks
Journal:  Iowa Orthop J       Date:  1998

8.  A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.

Authors:  M E Weinblatt; J M Kremer; A D Bankhurst; K J Bulpitt; R M Fleischmann; R I Fox; C G Jackson; M Lange; D J Burge
Journal:  N Engl J Med       Date:  1999-01-28       Impact factor: 91.245

9.  Diagnostic features of diffuse pigmented villonodular synovitis of the knee.

Authors:  F Flandry; J C Hughston; S B McCann; D M Kurtz
Journal:  Clin Orthop Relat Res       Date:  1994-01       Impact factor: 4.176

10.  Localized pigmented villonodular synovitis of the knee.

Authors:  Isik Akgün; Tahir Ogüt; Hayrettin Kesmezacar; Sergülen Dervisoglu
Journal:  Orthopedics       Date:  2003-11       Impact factor: 1.390

View more
  2 in total

Review 1.  Cross-Communication Between Knee Osteoarthritis and Fibrosis: Molecular Pathways and Key Molecules.

Authors:  Ioanna K Bolia; Kevin Mertz; Ethan Faye; Justin Sheppard; Sagar Telang; Jacob Bogdanov; Laith K Hasan; Aryan Haratian; Denis Evseenko; Alexander E Weber; Frank A Petrigliano
Journal:  Open Access J Sports Med       Date:  2022-03-01

2.  Update on Tenosynovial Giant Cell Tumor, an Inflammatory Arthritis With Neoplastic Features.

Authors:  Marie Robert; Helena Farese; Pierre Miossec
Journal:  Front Immunol       Date:  2022-02-21       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.